 **Medical Articles**


> Source: Science


**Topic: First generic twice-yearly HIV prevention injection receives FDA approval**

The U.S. FDA has granted tentative approval to the first generic version of **lenacapavir**, a long-acting injectable for HIV pre-exposure prophylaxis (PrEP), developed by India's Dr. Reddy's Laboratories. Administered twice yearly, lenacapavir offers an alternative to daily oral PrEP, with clinical trials demonstrating near-complete protection against HIV acquisition.
The generic is expected to cost approximately **US&#036;40 per person annually** and could become available across 120 low- and middle-income countries covered by voluntary licensing agreements. Initial supplies are expected by the end of 2026, with broader availability in 2027. This could significantly expand access, particularly in regions with a high HIV burden, including sub-Saharan Africa.

**Link:** [https://www.science.org/content/article/u-s-approval-cheap-generic-hiv-prevention-shot-may-boost-global-rollout](https://www.science.org/content/article/u-s-approval-cheap-generic-hiv-prevention-shot-may-boost-global-rollout)

[@HakimApps_Guideline](https://t.me/HakimApps_Guideline)